Stock AnalizKorsana Biosciences, Inc. KRSA
Biotechnology: Pharmaceutical Preparations · data as of November 13, 2026
Korsana Biosciences, Inc. (KRSA) is a healthcare company listed in the US with a market value of about $1.4B. In fiscal year 2025 it had revenue of $2M and net income of -$4M, a net margin of -170.1%.
Its overall Stock Analiz score is 1.2 out of 5 (weak). The strongest part is financial health (4/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of -2% a year, a 5-year average ROIC of -90%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 100% below the current price.
Score: 1.2 / 5
Checks passed
- 3-year revenue growth above 10% a year
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Interest covered more than 5 times
- Debt below 3 years of free cash flow
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- Profit margin improving
- 3-year free cash flow growth above 10% a year
Valuation
Growth and quality
Financials, last 8 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2M | $2M | $0 | $297000 | $4M | $2M | $5M | — |
| Net income | -$4M | -$3M | -$5M | -$44M | -$52M | -$78M | -$123M | -$115M |
| Free cash flow | — | — | — | -$41M | -$37M | -$74M | -$109M | -$101M |
| EPS (diluted) | $-0.07 | $-0.08 | $-0.15 | $-1.35 | $-1.76 | $-3.41 | $-5.99 | $-0.01 |
| Net margin | -170.1% | -152.8% | — | -14841.1% | -1310.2% | -3388.6% | -2729.3% | — |
| ROIC | -54.7% | -41.0% | -114.7% | -132.9% | -106.7% | -77.2% | -72.8% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 5 analysts is $44.00, 39% above the current price; targets range from $8.00 to $70.00; the consensus rating is “Strong buy”; expected EPS is $-1.70 for the fiscal year ending December 31, 2026.
Frequently asked questions
Is Korsana Biosciences stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 100% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Korsana Biosciences pay a dividend?
Not currently.
Is Korsana Biosciences a good stock to buy?
We do not give buy or sell advice. Korsana Biosciences scores 1.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.